载脂蛋白 E 多态性在左旋多巴诱导的运动障碍中的作用。

The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.

机构信息

Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Tel-Aviv, Israel.

出版信息

Acta Neurol Scand. 2011 Feb;123(2):117-21. doi: 10.1111/j.1600-0404.2010.01352.x.

DOI:10.1111/j.1600-0404.2010.01352.x

PMID:21108621

Abstract

OBJECTIVES

To determine the relationship between apolipoprotein E (APOE) polymorphisms to the time to appearance of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

METHODS

The APOE genotype of 155 consecutive patients treated with levodopa was determined and its effect on the time of onset of LID was examined using Cox regression model, controlling for gender, age of disease onset, time to initiation of levodopa treatment and history of smoking.

RESULTS

Two patients were homozygous for the APOE ε2 allele, 7 had ε2/ε3, 1 had ε2/ε4, 130 had ε3/ε3, 12 had ε3/ε4 and 3 had ε4/ε4; LID appeared in 57.4% of the patients, appearing 4.1 ± 3.5 years after the initiation of levodopa treatment. The survival curve for LID was not affected by the APOE genotype (P = 0.34).

CONCLUSION

APOE polymorphisms were found not to be associated with either the occurrence or the time to development of LID.

摘要

目的

确定载脂蛋白 E (APOE) 多态性与帕金森病患者出现左旋多巴诱导的运动障碍 (LID) 的时间之间的关系。

方法

确定了 155 例连续接受左旋多巴治疗的患者的 APOE 基因型，并使用 Cox 回归模型检查其对 LID 发病时间的影响，同时控制性别、疾病发病年龄、开始左旋多巴治疗时间和吸烟史。

结果

2 例患者为 APOE ε2 等位基因纯合子，7 例为 ε2/ε3，1 例为 ε2/ε4，130 例为 ε3/ε3，12 例为 ε3/ε4，3 例为 ε4/ε4；57.4%的患者出现 LID，在开始左旋多巴治疗后 4.1 ± 3.5 年出现。LID 的生存曲线不受 APOE 基因型的影响（P = 0.34）。